Vorsetuzumab mafodotin
As of the edition of 20 October 2026, Vorsetuzumab mafodotin is an antibody drug conjugate: stopped in 2013; acts on CD70.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Antibody drug conjugate
- Registered trials
- 2, 1 stopped early
- Disease areas
- Cancer; Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Immune system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Vorsetuzumab mafodotin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD70 | CD70 antigen | P32970 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| All trials | 2 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pfizer | Lead sponsor of trials | 2009 to now |